Risk of breast cancer in Lynch syndrome: a systematic review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction: Lynch syndrome is an autosomal dominantly inherited disorder of cancer susceptibility caused by germline mutations in the DNA mismatch repair (MMR) genes. Mutation carriers have a substantial burden of increased risks of cancers of the colon, rectum, endometrium and several other organs which generally occur at younger ages than for the general population. The issue of whether breast cancer risk is increased for MMR gene mutation carriers has been debated with evidence for and against this association. Methods: Using the PUBMED, we identified all relevant studies of breast cancer associated with Lynch syndrome that were published by 15 December 2012. In the review, we included: (i) molecular studies that reported microsatellite instability and/or immunohistochemistry in breast cancer tumors of MMR gene mutation carriers; and (ii) risk studies that investigated risk of breast cancer for confirmed MMR gene mutation carriers or families or clinically and/or pathologically defined Lynch syndrome families. Results: We identified 15 molecular studies and, when combined, observed 62 of 122 (51%; 95% CI 42 to 60%) breast cancers in MMR gene mutation carriers were MMR-deficient. Of the 21 risk studies identified, 13 did not observe statistical evidence for an association of breast cancer risk with Lynch syndrome while 8 studies found an increased risk of breast cancer ranging from 2- to 18-fold compared with the general population (or non-carriers). There is only one prospective study demonstrating an elevated risk of breast cancer for MMR gene mutation carriers compared with the general population (standardized incidence ratio 3.95; 95% CI 1.59, 8.13). Conclusions: Since breast cancer is a relatively common disease in the general population, more precise estimates of risk and gene-specific risks will need to utilize large prospective cohort studies with a long follow-up. While current data are inconclusive at a population level, individual tumor testing results suggest that MMR deficiency is involved with breast cancers in some individuals with Lynch syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Pancreatic Cancer in Families With Lynch Syndrome
Kastrinos, F. (2009) · JAMA · doi:10.1001/jama.2009.1529 · Cited by 544
Karamurzin, Y., Zeng, Z., Stadler, Z. K., Zhang, L., Ouansafi, I., Al-Ahmadie, H. A., Sempoux, C., Saltz, L. B., Soslow, R. A., O'Reilly, E. M., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.012 · Cited by 112 · cited 1×
“These cancers include adrenocortical adenocarcinoma [9-11], thyroid carcinoma [10], peritoneal mesothelioma [11], malignant fibrohistiocytoma [12,13], rhabdomyosarcoma [14], dermatofibrosarcoma [15], leiomyosarcoma [16-19], liposarcoma [19], carcinoid tumour [20], non-Hodgkin lymphoma [21], malignant melanoma [22], pa…”
BackgroundUnusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome
Broaddus, R. R., Lynch, P. M., Lu, K. H., Luthra, R., & Michelson, S. J. (2004) · Modern Pathology · doi:10.1038/modpathol.3800150 · Cited by 69 · cited 1×
“These cancers include adrenocortical adenocarcinoma [9-11], thyroid carcinoma [10], peritoneal mesothelioma [11], malignant fibrohistiocytoma [12,13], rhabdomyosarcoma [14], dermatofibrosarcoma [15], leiomyosarcoma [16-19], liposarcoma [19], carcinoid tumour [20], non-Hodgkin lymphoma [21], malignant melanoma [22], pa…”
BackgroundAdrenocortical adenocarcinoma in an MSH2 carrier: coincidence or causal relation?
Berends, M. (2000) · Human Pathology · doi:10.1053/hupa.2000.20409 · Cited by 33 · cited 1×
“These cancers include adrenocortical adenocarcinoma [9-11], thyroid carcinoma [10], peritoneal mesothelioma [11], malignant fibrohistiocytoma [12,13], rhabdomyosarcoma [14], dermatofibrosarcoma [15], leiomyosarcoma [16-19], liposarcoma [19], carcinoid tumour [20], non-Hodgkin lymphoma [21], malignant melanoma [22], pa…”
Background
Cited by
Saam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 920
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., Hallberg, E., Moore, R., Thomas, A., Lilyquist, J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0424 · Cited by 611
Provenzale, D., Gupta, S., Ahnen, D. J., Bray, T., Cannon, J. A., Cooper, G., David, D. S., Early, D. S., Erwin, D., Ford, J. M., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0108 · Cited by 255
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Davies, H., Morganella, S., Purdie, C. A., Jang, S. J., Borgen, E., Russnes, H., Glodzik, D., Zou, X., Viari, A., Richardson, A. L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1083 · Cited by 99
Metadata
- Authors
- Win, A. K., Lindor, N. M., & Jenkins, M. A.
- Venue
- Breast Cancer Research
- Published
- 2013-03-19
- Volume
- 15
- Issue
- 2
- Pages
- R27-R27
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1975790519
- Cited by
- 129
- References
- 4
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.